Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck Revenues up 22% for the Year to $59.3B | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Merck Revenues up 22% for the Year to $59.3B

Pharmaceutical sales top $52.0 billion for the year, up 22% driven by Keytruda; LAGEVRIO (molnupiravir) sales drop 13% in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
4Q Revenues: $13.8 billion (+2%)
4Q Earnings: $3.0 billion (-21%)
FY Revenues: $59.3 billion (+22%)
FY Earnings: $14.5 billion (+18%)
Comments: Pharmaceutical sales were $12.2 billion in the quarter, up 1% and $52.0 billion for the year, up 22%. Keytruda sales were $5.5 billion in the quarter, up 19% and $20.9 billion for the year, up 22%. GARDASIL sales were $1.5 billion int he quarter, down 4% and $6.9 billion for the year, up 22%. LAGEVRIO sales were $825 million in the quarter, down 13% and $5.7 billion for the year, >100%. JANUVIA / JANUMET sales were $913 million in the quarter, down 34%, and $4.5 billion for the year, down 15%. PROQUAD, M-M-R II and VARIVAX sales were $26 million in the quarter, up 3%, and $2.2 billion for the year, up 5%. BRIDION sales were $441 million in the quarter, up 1% and $1.7 billion for the year, up 10%.  ROTATEQ sales were down 35% to $139 million in the quarter, and down 3% for the year to $783 million. SIMPONI sales were down 19% in the quarter to $166 million and down 14% for the year to $706 million.
 
Pharmaceutical sales growth was partially offset by lower sales of JANUVIA and JANUMET for the treatment of type 2 diabetes, primarily reflecting generic competition, lower demand and net pricing in the U.S.
 
Sales of LAGEVRIO (molnupiravir), an investigational oral antiviral COVID-19 medicine, decreased 13% to $825 million in the quarter. Excluding the unfavorable impact of foreign exchange, sales increased 2%, primarily driven by strong growth in Japan and the U.K. and the launch in Australia, offset by a decline in the U.S.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters